Insulin Efsitora Alfa vs Insulin glargine (Toujeo)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline

Insulin Efsitora Alfa · Onswik

Marketed by Eli Lilly

Approved in Type 2 Diabetesprotein (Fc-fusion)
Partial signal

NCT05275400 · Phase 3 · completed

The study randomized 986 participants to efsitora or active-control insulin degludec, but treatment was open-label rather than blinded. The primary HbA1c noninferiority endpoint was met, with a treatment difference of -0.089 percentage points and a 95% confidence interval of -0.191 to 0.013 within the prespecified 0.4% margin; the primary endpoint was a surrogate measure.

Reported efficacy

Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Efsitora -1.19 Percentage of HbA1c (Standard Error 0.0546) vs Glargine -1.16 Percentage of HbA1c (Standard Error 0.0545) (met)

Result source: NCT05662332

Insulin glargine (Toujeo)

Marketed by Sanofi

Approved in Type 2 Diabetespeptide
Partial signal

NCT01499082 · Phase 3 · completed

The trial was large and randomized, with an active insulin glargine comparator, and its primary HbA1c endpoint was a hard clinical treatment measure that met the prespecified non-inferiority margin. However, treatment was open-label rather than double-blinded, so the evidence is considered moderate despite the favorable non-inferiority result.

Reported efficacy

Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): HOE901-U300 -0.83 percentage of hemoglobin (Standard Error 0.06) | Lantus -0.83 percentage of hemoglobin (Standard Error 0.061) (met)

Result source: NCT01499082

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointInsulin Efsitora AlfaInsulin glargine (Toujeo)
HbA1c, change-1.3% vs -1.2%vs Insulin Degludecwk 52 · n 463NCT05362058
11 other results
  • -1.2% vs -1.2% wk 52 · n 355 · Phase 3 · primary NCT05662332
  • -0.8% vs -0.7% 500 U/mL · wk 26 · n 649 · Phase 3 · primary NCT05275400
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · primary NCT05462756
  • -1.3% vs -1.2% wk 52 · n 463 · Phase 3 · secondary NCT05362058
  • -1.2% vs -1.2% wk 52 · n 355 · Phase 3 · secondary NCT05662332
  • -0.8% vs -0.7% 500 U/mL · wk 26 · n 649 · Phase 3 · secondary NCT05275400
  • -1.4% vs -1.3% wk 26 · n 463 · Phase 3 · secondary NCT05362058
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · secondary NCT05462756
  • -0.6% vs -0.7% wk 32 · n 130 · Phase 2 · primary NCT03736785
  • -0.6% vs -0.7% wk 32 · n 125 · Phase 2 · primary NCT03736785
  • -1.2% vs -1.3% wk 26 · n 127 · Phase 2 · primary NCT04450394
—Not reported
Body weight, change (kg)2.3 vs 2.2vs Insulin Degludec500 U/mL · wk 78 · n 654NCT05275400
6 other results
  • 3.6 vs 3.5 wk 52 · n 465 · Phase 3 · secondary NCT05362058
  • 3.9 vs 3.3 wk 52 · n 357 · Phase 3 · secondary NCT05662332
  • 3.2 vs 2.7 wk 26 · n 465 · Phase 3 · secondary NCT05362058
  • 2.7 vs 2.5 wk 26 · n 365 · Phase 3 · secondary NCT05462756
  • 1 vs 2 wk 32 · n 135 · Phase 2 · secondary NCT03736785
  • 1 vs 2 wk 32 · n 130 · Phase 2 · secondary NCT03736785
—Not reported
HbA1c below 7%—Not reported—Not reported
Fasting plasma glucose, change—Not reported—Not reported
3-point MACE (% with event)—Not reported—Not reported

HbA1c, change

Insulin Efsitora Alfa
-1.3% vs -1.2%vs Insulin Degludecwk 52 · n 463NCT05362058
11 other results
  • -1.2% vs -1.2% wk 52 · n 355 · Phase 3 · primary NCT05662332
  • -0.8% vs -0.7% 500 U/mL · wk 26 · n 649 · Phase 3 · primary NCT05275400
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · primary NCT05462756
  • -1.3% vs -1.2% wk 52 · n 463 · Phase 3 · secondary NCT05362058
  • -1.2% vs -1.2% wk 52 · n 355 · Phase 3 · secondary NCT05662332
  • -0.8% vs -0.7% 500 U/mL · wk 26 · n 649 · Phase 3 · secondary NCT05275400
  • -1.4% vs -1.3% wk 26 · n 463 · Phase 3 · secondary NCT05362058
  • -1.0% vs -1% wk 26 · n 361 · Phase 3 · secondary NCT05462756
  • -0.6% vs -0.7% wk 32 · n 130 · Phase 2 · primary NCT03736785
  • -0.6% vs -0.7% wk 32 · n 125 · Phase 2 · primary NCT03736785
  • -1.2% vs -1.3% wk 26 · n 127 · Phase 2 · primary NCT04450394
Insulin glargine (Toujeo)
—Not reported

Body weight, change (kg)

Insulin Efsitora Alfa
2.3 vs 2.2vs Insulin Degludec500 U/mL · wk 78 · n 654NCT05275400
6 other results
  • 3.6 vs 3.5 wk 52 · n 465 · Phase 3 · secondary NCT05362058
  • 3.9 vs 3.3 wk 52 · n 357 · Phase 3 · secondary NCT05662332
  • 3.2 vs 2.7 wk 26 · n 465 · Phase 3 · secondary NCT05362058
  • 2.7 vs 2.5 wk 26 · n 365 · Phase 3 · secondary NCT05462756
  • 1 vs 2 wk 32 · n 135 · Phase 2 · secondary NCT03736785
  • 1 vs 2 wk 32 · n 130 · Phase 2 · secondary NCT03736785
Insulin glargine (Toujeo)
—Not reported

HbA1c below 7%

Insulin Efsitora Alfa
—Not reported
Insulin glargine (Toujeo)
—Not reported

Fasting plasma glucose, change

Insulin Efsitora Alfa
—Not reported
Insulin glargine (Toujeo)
—Not reported

3-point MACE (% with event)

Insulin Efsitora Alfa
—Not reported
Insulin glargine (Toujeo)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. Insulin Efsitora Alfa: 6 of 6 rows · Insulin glargine (Toujeo): 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricInsulin Efsitora Alfa
Rows use multiple source trials
Insulin glargine (Toujeo)
Hypoglycemia Event Incidence
responder rate · % of participants
25.94% (n=397) vs 29.9% (n=398) Glargine @ 52wka,b,c,d
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
8.7% (n=92) vs 9.5% (n=84) Glargine U100 @ 12wka,b,c,d
NCT03013985 · Phase 4 · registry result, not featured evidence
Time in Range
absolute value · percentage points
64.27% (n=387) vs 61.18% (n=381) Insulin Degludec @ 52wka,b,c,d
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
50.3% (n=92) vs 54.9% (n=84) Glargine U100 @ 12wka,b,c,d
NCT03013985 · Phase 4 · registry result, not featured evidence
Dropout rate
9.5%500 U/mLe
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 8 more results
5.4%
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—Efsitora
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
8.8%Insulin Efsitora Alfa
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
4.7%
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
7.8%LY3209590 Algorithm 1 (Paper)
NCT04450394 · Phase 2 · registry result, not featured evidence
0%LY3209590 Algorithm 2 (Digital)
NCT04450394 · Phase 2 · registry result, not featured evidence
12.6%LY3209590 Algorithm 1
NCT03736785 · Phase 2 · registry result, not featured evidence
12.9%LY3209590 Algorithm 2
NCT03736785 · Phase 2 · registry result, not featured evidence
14.8%f
NCT03013985 · Phase 4 · registry result, not featured evidence
show 1 more result
14.9%
NCT02451137 · Phase 4 · registry result, not featured evidence
Discontinued due to AEs
1.1%500 U/mLe
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 8 more results
0.6%
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—Efsitora
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—Insulin Efsitora Alfa
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0.8%
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.6%LY3209590 Algorithm 1 (Paper)
NCT04450394 · Phase 2 · registry result, not featured evidence
0%LY3209590 Algorithm 2 (Digital)
NCT04450394 · Phase 2 · registry result, not featured evidence
0.7%LY3209590 Algorithm 1
NCT03736785 · Phase 2 · registry result, not featured evidence
0.8%LY3209590 Algorithm 2
NCT03736785 · Phase 2 · registry result, not featured evidence
—f
NCT03013985 · Phase 4 · registry result, not featured evidence
show 1 more result
2.6%
NCT02451137 · Phase 4 · registry result, not featured evidence
Serious AEs
15.7%500 U/mLe
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 8 more results
8.8%
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
6.5%Efsitora
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—Insulin Efsitora Alfa
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
6.8%
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
4.7%LY3209590 Algorithm 1 (Paper)
NCT04450394 · Phase 2 · registry result, not featured evidence
7.1%LY3209590 Algorithm 2 (Digital)
NCT04450394 · Phase 2 · registry result, not featured evidence
5.2%LY3209590 Algorithm 1
NCT03736785 · Phase 2 · registry result, not featured evidence
6.1%LY3209590 Algorithm 2
NCT03736785 · Phase 2 · registry result, not featured evidence
19.4%f
NCT03013985 · Phase 4 · registry result, not featured evidence
show 1 more result
9.8%
NCT02451137 · Phase 4 · registry result, not featured evidence
Most frequent reported AEs
500 U/mLe
covid-19 10.7%
nasopharyngitis 9.2%
dose calculation error 6.4%
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 7 more results
nasopharyngitis 9.2%
covid-19 7.9%
upper respiratory tract infection 7.9%
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
influenza 7.3%
covid-19 5.3%
hypertension 5.3%
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
nasopharyngitis 6.3%
influenza 3.8%
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
anaemia 4.7%
arthralgia 2.3%
diarrhoea 2.3%
NCT04450394 · Phase 2 · registry result, not featured evidence
abdominal discomfort 7.1%
anaemia 7.1%
chest pain 7.1%
NCT04450394 · Phase 2 · registry result, not featured evidence
diarrhoea 6.7%
upper respiratory tract infection 5.9%
cough 0.7%
NCT03736785 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 10.6%
diarrhoea 6.1%
dizziness 5.3%
NCT03736785 · Phase 2 · registry result, not featured evidence
f
trauma 3.7%
cough 0.9%
gastroparesis 0.9%
NCT03013985 · Phase 4 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 3 versus Phase 4.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 52 weeks versus 12 weeks.
  5. ePopulation comparability has not been reviewed for 4 of these studies.
  6. fPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Insulin Efsitora Alfa

HbA1c -0.81% (n=649) vs -0.72% (n=328) Insulin Degludec @ 26wk500 U/mL
absolute change · percentage points
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 11 more results
-0.81% (n=649) vs -0.72% (n=328) Insulin Degludec @ 26wk500 U/mL
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-1.26% (n=463) vs -1.17% (n=458) Insulin Degludec @ 52wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-1.26% (n=463) vs -1.17% (n=458) Insulin Degludec @ 52wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-1.37% (n=463) vs -1.3% (n=458) Insulin Degludec @ 26wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-1.19% (n=355) vs -1.16% (n=360) Glargine @ 52wk
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-1.19% (n=355) vs -1.16% (n=360) Glargine @ 52wk
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-1.01% (n=361) vs -1% (n=362) Insulin Glargine @ 26wk
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.01% (n=361) vs -1% (n=362) Insulin Glargine @ 26wk
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.2% (n=127) vs -1.26% (n=130) Insulin Degludec @ 26wk
NCT04450394 · Phase 2 · registry result, not featured evidence
-0.58% (n=130) vs -0.66% (n=124) Insulin Degludec @ 32wk
NCT03736785 · Phase 2 · registry result, not featured evidence
-0.57% (n=125) vs -0.66% (n=124) Insulin Degludec @ 32wk
NCT03736785 · Phase 2 · registry result, not featured evidence
Fasting Glucose Change mg/dL -30.97 vs -30.13 Insulin Degludec mg @ 26wk500 U/mL
absolute change · mg
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 4 more results
-46.76 vs -50.92 Glargine mg @ 52wk
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-30.87 vs -26.58 Insulin Glargine mg @ 26wk
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
-13.1 vs -31.5 Insulin Degludec mg @ 32wk
NCT03736785 · Phase 2 · registry result, not featured evidence
-18.6 vs -31.5 Insulin Degludec mg @ 32wk
NCT03736785 · Phase 2 · registry result, not featured evidence
Weight 2.27 vs 2.2 Insulin Degludec kg @ 78wk500 U/mL
absolute change · kg
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 6 more results
3.16 vs 2.66 Insulin Degludec kg @ 26wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
3.6 vs 3.54 Insulin Degludec kg @ 52wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
3.86 vs 3.29 Glargine kg @ 52wk
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
2.67 vs 2.53 Insulin Glargine kg @ 26wk
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
1 vs 2 Insulin Degludec kg @ 32wk
NCT03736785 · Phase 2 · registry result, not featured evidence
1 vs 2 Insulin Degludec kg @ 32wk
NCT03736785 · Phase 2 · registry result, not featured evidence
Time Below Range 0.36 vs 0.22 Insulin Degludec % of time @ 26wk500 U/mL
absolute value · % of time
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
6.84 vs 5.25 Insulin Glargine % of time @ 26wk
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time Above Range 37.25 vs 38.24 Insulin Degludec % of time @ 26wk500 U/mL
absolute value · % of time
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 4 more results
31.99 vs 32.4 Insulin Degludec % of time @ 12wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
28.93 vs 29.87 Insulin Degludec % of time @ 26wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
29.66 vs 33.05 Insulin Degludec % of time @ 52wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
40.1 vs 41.6 Insulin Glargine % of time @ 26wk
NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3
TRIM-D 10.03 vs 6.88 Insulin Degludec score @ 26wk500 U/mL
absolute change · score
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 3 more results
10.09 vs 6.53 Insulin Degludec score @ 52wk500 U/mL
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
10.33 vs 6.98 Insulin Degludec score @ 78wk500 U/mL
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
15.4 vs 13.87 Glargine score @ 52wk
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
DTSQc - Treatment Satisfaction 14.9 vs 12.3 Insulin Degludec score @ 26wk500 U/mL
absolute value · score
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
15.1 vs 12.3 Insulin Degludec score @ 52wk500 U/mL
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
15.4 vs 11.7 Insulin Degludec score @ 78wk500 U/mL
NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
FBG Change mg/dL -57.86 vs -63.04 Insulin Degludec mg @ 26wk
absolute change · mg
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
-59.77 vs -59.97 Insulin Degludec mg @ 52wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Glucose Variability CV 26.31% (n=368) vs 26.67% (n=360) Insulin Degludec @ 26wk
absolute value · percentage points
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
26.29% (n=368) vs 26.81% (n=360) Insulin Degludec @ 52wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Time Below 70 mg/dL 1.06% (n=368) vs 0.93% (n=360) Insulin Degludec @ 12wk
absolute value · percentage points
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
1.55% (n=368) vs 1.25% (n=360) Insulin Degludec @ 26wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
1.49% (n=368) vs 1.19% (n=360) Insulin Degludec @ 52wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Time Below 54 mg/dL 0.24% (n=368) vs 0.27% (n=360) Insulin Degludec @ 12wk
absolute value · percentage points
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 2 more results
0.33% (n=368) vs 0.28% (n=360) Insulin Degludec @ 26wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0.32% (n=368) vs 0.3% (n=360) Insulin Degludec @ 52wk
NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Nocturnal Hypoglycemia Incidence 3.53% (n=397) vs 5.03% (n=398) Glargine @ 52wk
responder rate · % of participants
NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3

+ 5 further endpoints in the CSV export.

Insulin glargine (Toujeo)

Daily Glucose mg/dL 10.32 vs 10.21 Glargine U100 mmol/L
absolute value · mmol/L
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 186 mg/dL as posted
show 6 more results
9.52 vs 9.13 Glargine U100 mmol/L @ 12wk*
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 171.6 mg/dL as posted
8.33 vs 7.46 Glargine U100 mmol/L @ 12wk*
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 150 mg/dL as posted
8.45 vs 8.64 Glargine U100 mmol/L @ 12wk*
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 152.3 mg/dL as posted
9.42 vs 10.92 Glargine U100 mmol/L*
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 169.71 mg/dL as posted
10.74 vs 10.75 Glargine U100 mmol/L*
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 193.53 mg/dL as posted
10.46 vs 9.69 Glargine U100 mmol/L*
NCT03013985 · Phase 4 · registry result, not featured evidence · converted to mmol/L from 188.46 mg/dL as posted
Severe Hypoglycemia Event Incidence 0% (n=92) vs 6% (n=84) Glargine U100 @ 12wk
responder rate · % of participants
NCT03013985 · Phase 4 · registry result, not featured evidence
HbA1c Target Attainment Without Hypoglycemia 31.3% (n=1651) @ 26wk
responder rate · % of participants
No placebo or comparator arm
NCT02451137 · Phase 4 · registry result, not featured evidence
show 1 more result
37.3% (n=1651) @ 26wk
NCT02451137 · Phase 4 · registry result, not featured evidence
HbA1c -1.4% (n=1651) @ 26wk
absolute change · percentage points
No placebo or comparator arm
NCT02451137 · Phase 4 · registry result, not featured evidence
show 1 more result
-1.29% (n=1651) @ 52wk
NCT02451137 · Phase 4 · registry result, not featured evidence
Fasting Plasma Glucose -2.71 mmol/L @ 26wk
absolute change · mmol/L
No placebo or comparator arm
NCT02451137 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -48.9 mg/dL as posted
show 1 more result
-2.66 mmol/L @ 52wk*
NCT02451137 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -48 mg/dL as posted
Weight 1.02 kg @ 26wk
absolute change · kg
No placebo or comparator arm
NCT02451137 · Phase 4 · registry result, not featured evidence
show 1 more result
1.51 kg @ 52wk
NCT02451137 · Phase 4 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin Efsitora Alfa's landscape · Insulin glargine (Toujeo)'s landscape